Because of its favourable pharmacokinetic profile Levetiracetam (LEV) is an almost ideal anticonvulsant agent particularly for multi-morbid Intensive Care Unit (ICU)'s patients. Objective of this study is to evaluate LEV's effectiveness in patients with Status Epilepticus (SE) undergoing continuous EEG monitoring. 15 pts admitted in our Hospital ICUs with SE (5 NonConvulsive SE - NCSE - and 10 Convulsive SE - CSE) undergoing Continuous EEG monitoring during treatment with LEV (titration dose from 1500 to 4500 mg/die) are included. We administrated LEV as first drug in 13 of 15 pts. 2 pts of this group showed electroclinical SE suppression. In 5 pts clinical features was abolished, but an epileptic continuous EEG pattern persisted. 2 cases with refractory SE was also unresponsives to LEV. We observed that LEV shows a partial efficacy in these hard-management cases. Our experience enphatizes the role of continuous EEG monitoring, that depicts an essential tool particulary to detect the persistence of subclinical epileptic activity despite the disappearance of any clinical feature after AEDs administration.
|Translated title of the contribution||Continuous EEG monitoring during status epilepticus treated with levetiracetam|
|Number of pages||3|
|Journal||Bollettino - Lega Italiana contro l'Epilessia|
|Publication status||Published - Apr 2010|
ASJC Scopus subject areas
- Clinical Neurology